EANM’26 | CGNNT Returns to the European Nuclear Medicine Congress, Showcasing CGN Hejia Isotopes on the Global Stage

From October 17 to 21, 2026, the 39th Annual Congress of the European Association of Nuclear Medicine (EANM’26) was held in Vienna, Austria. Following its debut at the congress in 2025, CGN Isotope (Mianyang) Technology Co., Ltd., a subsidiary of CGN Nuclear Technology Development Co., Ltd. (CGNNT), returned to this prestigious international event with a portfolio of key medical isotope products. The company showcased its CGN Hejia® Germanium-68 (Ge-68) solution, Germanium-68/Gallium-68 (Ge-68/Ga-68) generators, and accompanying automated elution systems, while also promoting a range of medical isotopes, including Oxygen-18 (O-18), Copper-64 (Cu-64), Zirconium-89 (Zr-89), and Iodine-123 (I-123).

                                                                      The 39th Annual Congress of the European Association of Nuclear Medicine (EANM’26)
At this year's exhibition, the physical displays of Ge-68/Ga-68 generators and automated elution systems highlighted CGNNT's technical expertise in the production and supply of critical medical isotopes and the development of supporting equipment. These exhibits attracted considerable attention from nuclear medicine experts and industry professionals, leading to in-depth discussions on product specifications, technical performance, and potential applications.

CGNNT representatives engage in discussions with international nuclear medicine experts and industry professionals.

Throughout the congress, nuclear medicine experts and industry representatives from Europe, Asia, and North America visited the CGNNT booth to explore potential cooperation opportunities. Discussions focused on production capacity, supply reliability, and market entry pathways for key products such as CGN Hejia® Ge-68, Ge-68/Ga-68 generators, and O-18. Several international partners expressed strong interest in CGNNT's medical isotope portfolio and a clear willingness to explore further collaboration. Preliminary discussions were also held on long-term supply arrangements, joint technology development, and regional market cooperation.

CGNNT representatives pose for a group photo with international nuclear medicine experts and industry partners.

From Barcelona to Vienna, CGNNT continues to strengthen its presence in the global nuclear medicine market. Looking ahead, the company will remain committed to its strategic focus on theranostics and precision targeting, further developing a comprehensive medical isotope portfolio encompassing diagnostic isotopes, therapeutic isotopes, and precursor isotopes. By providing global customers with a stable supply of high-quality, reliable medical isotopes, CGNNT aims to deepen collaboration with partners across the industry value chain and contribute to the innovative development and clinical translation of radiopharmaceuticals worldwide.